Monday, February 05, 2024
Fermion, a clinical-stage pharmaceutical company focused on autoimmune diseases and pain management, is delighted to announce the approval of its Investigational New Drug (IND) application for FZ007-119 by the China National Medical Products Administration (NMPA). This marks Fermion's third successful IND approval since its inception.
FZ007-119 is a TYK2 JH2 inhibitor, developed using Fermion's proprietary Drug Studio AI drug development platform. Preclinical studies have shown that FZ007-119 exhibits high selectivity for JAK1-3, suggesting potential for improved clinical efficacy and safety. Its selectivity positions it as a potential Best in Class (BIC) candidate.
Since its founding in 2019, Fermion has focused on developing innovative products for CNS and autoimmune diseases. In the autoimmune field, Fermion has established pipelines targeting various conditions including psoriasis, inflammatory bowel disease, and rheumatoid arthritis. FZ007-119 is the most rapidly advancing pipeline in this area.
Fermion, highlighted the significance of FZ007-119's selectivity compared to existing drugs targeting the same receptor, emphasizing its potential as a Best in Class option.
Fermion's IND approval for FZ007-119 represents a milestone in its commitment to developing innovative treatments for autoimmune diseases, showcasing its leadership in this field.